Physitrack: Steady state - Redeye

Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which came in close to our forecasts. We find the c25% organic growth, combined with effective cost management in the face of ongoing challenging market conditions, to be encouraging. We raise our base case to SEK41(SEK38) per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/915765/physitrack-steady-state?utm_source=finwire&utm_medium=RSS